Avisa Diagnostics Inc
CNSX:AVBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AVBT's latest stock split occurred on May 18, 2021
The company executed a 1-for-15 stock split, meaning that for every 15 shares held, investors received 1 new share.
Before the split, AVBT traded at 0.825 per share. Afterward, the share price was about 0.825.
The adjusted shares began trading on May 18, 2021. This was AVBT's 4th stock split, following the previous one in May 29, 2018.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 23, 2026
|
|
Red Sky Energy Ltd
ASX:ROG
|
5-for-4
x1.25
|
0.002 0.0016 AUD | 0.002 0.002 AUD |
|
Apr 23, 2026
|
J
|
Jiusheng Electric Co Ltd
SZSE:301082
|
1-for-1
x1
|
17.33 13.2508 CNY | 12.9 12.9 CNY |
|
Apr 23, 2026
|
S
|
Saudee Group Bhd
KLSE:SAUDEE
|
1-for-10
/10
|
0.01 0.1 MYR | 0.09 0.09 MYR |
|
Apr 23, 2026
|
|
Focus Technology Co Ltd
SZSE:002315
|
1-for-1
x1
|
44.3999 33.4538 CNY | 32 32 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
ROG
002315
Avisa Diagnostics Inc
Glance View
Avisa Diagnostics, Inc. is a clinical stage medical device company. The company is headquartered in Santa Fe, New Mexico. The company went IPO on 2010-02-16. The firm develops the Avisa BreathTest, a drug/device biomarker technology platform that enables the detection of bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates. The firm conducts trials in cystic fibrosis, tuberculosis and community-acquired pneumonia. Its drug/device is in late-stage clinical development, which measures the lung and live organisms. The firm develops, AVISARTM instrument, which contains a touchscreen operator interface, nebulizer controller, breath sampling pneumatics and a laser spectrometer. Its Avisa BreathTest kit contains lyophilized AV-U13 drug, pre-filled syringe of sterile water, breath collection and biologic filter components and aerogen solo mesh nebulizer.
